RCUS
Arcus Biosciences, Inc.
Price Chart
Latest Quote
$26.64
-1.38 (-4.93%)
Current Price
| Previous Close | $28.02 |
| Open | $27.52 |
| Day High | $27.71 |
| Day Low | $26.47 |
| Volume | 1,035,146 |
Stock Information
| Shares Outstanding | 125.77M |
| Total Debt | $232.00M |
| Cash Equivalents | $822.00M |
| Revenue | $236.00M |
| Net Income | $-369.00M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.44B |
| EPS (TTM) | $-3.26 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.85B |
| Sales | $236.00M |
| Income | $-369.00M |
| Book/sh | $4.17 |
| Cash/sh | $6.54 |
| Employees | 601 |
Financial Ratios
| Quick Ratio | 3.97 |
| Current Ratio | 4.04 |
| Debt/Eq | 44.27 |
Returns & Margins
| ROA | -23.11% |
| ROE | -69.95% |
| Gross Margin | -121.61% |
| Operating Margin | -788.24% |
| Profit Margin | -156.36% |
Ownership
| Insider Ownership | 29.15% |
| Institutional Ownership | 72.33% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.82 |
| P/S | 14.59 |
| P/B | 6.56 |
Analyst Data
| Recommendation | none |
| Target Price | $35.75 |
Technical Indicators
| SMA20 | $28.94 |
| SMA50 | $26.07 |
| SMA200 | $22.58 |
| RSI | 30.16 |
| ATR | 1.4300 |
| Shares Float | 88.98M |
| Short Float | 16.54% |
| Short Ratio | 7.62 |
| Volatility | 0.80 |
| Rel Volume | 0.49 |
Performance History
| Week | -5.36% |
| Month | +16.22% |
| Quarter | +16.02% |
| 6 Months | +11.44% |
| YTD | +17.52% |
| Year | +195.57% |
| 3 Years | +16.27% |
| 5 Years | -5.85% |
| 10 Years | +61.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $27.37 | 781,600 |
| 2026-07-16 | $26.64 | 1,303,100 |
| 2026-07-15 | $28.02 | 718,700 |
| 2026-07-14 | $28.33 | 802,000 |
| 2026-07-13 | $28.07 | 954,800 |
| 2026-07-10 | $28.92 | 811,700 |
| 2026-07-09 | $29.96 | 753,400 |
| 2026-07-08 | $30.26 | 1,135,900 |
| 2026-07-07 | $30.25 | 794,200 |
| 2026-07-06 | $29.98 | 762,000 |
| 2026-07-02 | $30.33 | 1,325,800 |
| 2026-07-01 | $28.92 | 1,664,800 |
| 2026-06-30 | $30.83 | 1,344,500 |
| 2026-06-29 | $31.08 | 1,565,100 |
| 2026-06-26 | $31.00 | 4,352,600 |
| 2026-06-25 | $30.25 | 2,509,200 |
| 2026-06-24 | $28.80 | 1,789,200 |
| 2026-06-23 | $28.18 | 2,341,900 |
| 2026-06-22 | $27.23 | 3,580,800 |
| 2026-06-18 | $24.31 | 2,309,000 |
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
đ° Latest News
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
Motley Fool âĸ 2026-07-13T23:29:17Z
Bristol-Myers Squibb (BMY) Joins Arcus Biosciences to Test a New Two-Drug Kidney Cancer Combination
Insider Monkey âĸ 2026-07-01T21:35:44Z
Bristol Myers Squibbâs AI Overhaul And Oncology Trials Shape Value Story
Simply Wall St. âĸ 2026-06-12T05:11:11Z
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Zacks âĸ 2026-06-04T15:53:00Z
How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook
Simply Wall St. âĸ 2026-05-21T12:17:37Z
Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts
Simply Wall St. âĸ 2026-05-16T14:03:51Z
Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report
Simply Wall St. âĸ 2026-05-08T14:03:57Z
Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift
Simply Wall St. âĸ 2026-05-06T06:09:19Z
Arcus Biosciences, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-06T00:21:07Z
Arcus (RCUS) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-05-05T22:38:55Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $247,000,000 | $258,000,000 | $117,000,000 | $112,000,000 |
| Operating Revenue | $247,000,000 | $258,000,000 | $117,000,000 | $112,000,000 |
| Expenses | ||||
| Interest Expense | $8,000,000 | $4,000,000 | $2,000,000 | $2,000,000 |
| Total Expenses | $633,000,000 | $568,000,000 | $457,000,000 | $392,000,000 |
| Net Non Operating Interest Income Expense | $33,000,000 | $48,000,000 | $39,000,000 | $14,000,000 |
| Interest Expense Non Operating | $8,000,000 | $4,000,000 | $2,000,000 | $2,000,000 |
| Operating Expense | $633,000,000 | $568,000,000 | $457,000,000 | $392,000,000 |
| General And Administrative Expense | $110,000,000 | $120,000,000 | $117,000,000 | $104,000,000 |
| Other Income Expense | - | $-20,000,000 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-353,000,000 | $-283,000,000 | $-307,000,000 | $-267,000,000 |
| Net Interest Income | $33,000,000 | $48,000,000 | $39,000,000 | $14,000,000 |
| Interest Income | $41,000,000 | $52,000,000 | $41,000,000 | $16,000,000 |
| Normalized Income | $-353,000,000 | $-267,200,000 | $-307,000,000 | $-267,000,000 |
| Net Income From Continuing And Discontinued Operation | $-353,000,000 | $-283,000,000 | $-307,000,000 | $-267,000,000 |
| Total Operating Income As Reported | $-386,000,000 | $-330,000,000 | $-340,000,000 | $-280,000,000 |
| Net Income Common Stockholders | $-353,000,000 | $-283,000,000 | $-307,000,000 | $-267,000,000 |
| Net Income | $-353,000,000 | $-283,000,000 | $-307,000,000 | $-267,000,000 |
| Net Income Including Noncontrolling Interests | $-353,000,000 | $-283,000,000 | $-307,000,000 | $-267,000,000 |
| Net Income Continuous Operations | $-353,000,000 | $-283,000,000 | $-307,000,000 | $-267,000,000 |
| Pretax Income | $-353,000,000 | $-282,000,000 | $-301,000,000 | $-266,000,000 |
| Special Income Charges | $0 | $-20,000,000 | $0 | $0 |
| Interest Income Non Operating | $41,000,000 | $52,000,000 | $41,000,000 | $16,000,000 |
| Operating Income | $-386,000,000 | $-310,000,000 | $-340,000,000 | $-280,000,000 |
| Earnings From Equity Interest | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-3.29 | $-3.14 | $-4.15 | $-3.71 |
| Basic EPS | $-3.29 | $-3.14 | $-4.15 | $-3.71 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-4,200,000 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-335,000,000 | $-248,000,000 | $-291,000,000 | $-258,000,000 |
| Total Unusual Items | $0 | $-20,000,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $-20,000,000 | $0 | $0 |
| Reconciled Depreciation | $10,000,000 | $10,000,000 | $8,000,000 | $6,000,000 |
| EBITDA (Bullshit earnings) | $-335,000,000 | $-268,000,000 | $-291,000,000 | $-258,000,000 |
| EBIT | $-345,000,000 | $-278,000,000 | $-299,000,000 | $-264,000,000 |
| Diluted Average Shares | $107,400,000 | $90,100,000 | $74,000,000 | $72,000,000 |
| Basic Average Shares | $107,400,000 | $90,100,000 | $74,000,000 | $72,000,000 |
| Diluted NI Availto Com Stockholders | $-353,000,000 | $-283,000,000 | $-307,000,000 | $-267,000,000 |
| Tax Provision | $0 | $1,000,000 | $6,000,000 | $1,000,000 |
| Impairment Of Capital Assets | $0 | $20,000,000 | $0 | $0 |
| Research And Development | $523,000,000 | $448,000,000 | $340,000,000 | $288,000,000 |
| Selling General And Administration | $110,000,000 | $120,000,000 | $117,000,000 | $104,000,000 |
| Other Gand A | $110,000,000 | $120,000,000 | $117,000,000 | $104,000,000 |
| Gain On Sale Of Business | - | - | - | - |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $631,000,000 | $485,000,000 | $462,000,000 | $657,000,000 |
| Total Assets | $1,139,000,000 | $1,150,000,000 | $1,095,000,000 | $1,345,000,000 |
| Total Non Current Assets | $132,000,000 | $134,000,000 | $264,000,000 | $278,000,000 |
| Other Non Current Assets | $63,000,000 | $73,000,000 | $106,000,000 | $114,000,000 |
| Investmentin Financial Assets | $29,000,000 | $14,000,000 | $107,000,000 | $129,000,000 |
| Current Assets | $1,007,000,000 | $1,016,000,000 | $831,000,000 | $1,067,000,000 |
| Other Current Assets | $10,000,000 | $13,000,000 | $30,000,000 | $15,000,000 |
| Receivables | $16,000,000 | $25,000,000 | $42,000,000 | $43,000,000 |
| Accrued Interest Receivable | $5,000,000 | $5,000,000 | $4,000,000 | $4,000,000 |
| Accounts Receivable | $11,000,000 | $20,000,000 | $38,000,000 | $39,000,000 |
| Cash Cash Equivalents And Short Term Investments | $981,000,000 | $978,000,000 | $759,000,000 | $1,009,000,000 |
| Cash And Cash Equivalents | $222,000,000 | $150,000,000 | $127,000,000 | $206,000,000 |
| Prepaid Assets | - | - | - | $15,000,000 |
| Debt | ||||
| Total Debt | $112,000,000 | $60,000,000 | $11,000,000 | $3,000,000 |
| Long Term Debt And Capital Lease Obligation | $99,000,000 | $48,000,000 | - | - |
| Long Term Debt | $99,000,000 | $48,000,000 | - | - |
| Current Debt And Capital Lease Obligation | $13,000,000 | $12,000,000 | $11,000,000 | $3,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $508,000,000 | $665,000,000 | $633,000,000 | $688,000,000 |
| Total Non Current Liabilities Net Minority Interest | $277,000,000 | $439,000,000 | $449,000,000 | $495,000,000 |
| Other Non Current Liabilities | $135,000,000 | $157,000,000 | $142,000,000 | $140,000,000 |
| Non Current Deferred Liabilities | $43,000,000 | $234,000,000 | $307,000,000 | $355,000,000 |
| Current Liabilities | $231,000,000 | $226,000,000 | $184,000,000 | $193,000,000 |
| Other Current Liabilities | $18,000,000 | $14,000,000 | $3,000,000 | $3,000,000 |
| Current Deferred Liabilities | $35,000,000 | $85,000,000 | $91,000,000 | $97,000,000 |
| Payables And Accrued Expenses | $165,000,000 | $115,000,000 | $79,000,000 | $90,000,000 |
| Payables | $43,000,000 | $19,000,000 | $17,000,000 | $20,000,000 |
| Total Tax Payable | $1,000,000 | $1,000,000 | $0 | $0 |
| Income Tax Payable | $1,000,000 | $1,000,000 | $0 | $0 |
| Accounts Payable | $42,000,000 | $18,000,000 | $17,000,000 | $20,000,000 |
| Equity | ||||
| Common Stock Equity | $631,000,000 | $485,000,000 | $462,000,000 | $657,000,000 |
| Total Equity Gross Minority Interest | $631,000,000 | $485,000,000 | $462,000,000 | $657,000,000 |
| Stockholders Equity | $631,000,000 | $485,000,000 | $462,000,000 | $657,000,000 |
| Retained Earnings | $-1,485,000,000 | $-1,132,000,000 | $-849,000,000 | $-542,000,000 |
| Gains Losses Not Affecting Retained Earnings | - | - | $0 | $-7,000,000 |
| Other Equity Adjustments | - | - | - | $-7,000,000 |
| Other | ||||
| Ordinary Shares Number | $125,300,000 | $92,200,000 | $75,500,000 | $72,900,000 |
| Share Issued | $125,300,000 | $92,200,000 | $75,500,000 | $72,900,000 |
| Tangible Book Value | $631,000,000 | $485,000,000 | $462,000,000 | $657,000,000 |
| Invested Capital | $730,000,000 | $533,000,000 | $462,000,000 | $657,000,000 |
| Working Capital | $776,000,000 | $790,000,000 | $647,000,000 | $874,000,000 |
| Capital Lease Obligations | $13,000,000 | $12,000,000 | $11,000,000 | $3,000,000 |
| Total Capitalization | $730,000,000 | $533,000,000 | $462,000,000 | $657,000,000 |
| Capital Stock | $2,116,000,000 | $1,617,000,000 | $1,311,000,000 | $1,206,000,000 |
| Common Stock | $2,116,000,000 | $1,617,000,000 | $1,311,000,000 | $1,206,000,000 |
| Non Current Deferred Revenue | $43,000,000 | $234,000,000 | $307,000,000 | $355,000,000 |
| Current Deferred Revenue | $35,000,000 | $85,000,000 | $91,000,000 | $97,000,000 |
| Current Capital Lease Obligation | $13,000,000 | $12,000,000 | $11,000,000 | $3,000,000 |
| Current Accrued Expenses | $122,000,000 | $96,000,000 | $62,000,000 | $70,000,000 |
| Investments And Advances | $29,000,000 | $14,000,000 | $107,000,000 | $129,000,000 |
| Available For Sale Securities | $29,000,000 | $14,000,000 | $107,000,000 | $129,000,000 |
| Net PPE | $40,000,000 | $47,000,000 | $51,000,000 | $35,000,000 |
| Accumulated Depreciation | $-50,000,000 | $-41,000,000 | $-31,000,000 | $-23,000,000 |
| Gross PPE | $90,000,000 | $88,000,000 | $82,000,000 | $58,000,000 |
| Leases | $57,000,000 | $56,000,000 | $54,000,000 | $34,000,000 |
| Construction In Progress | $1,000,000 | $1,000,000 | $1,000,000 | $4,000,000 |
| Other Properties | $28,000,000 | $27,000,000 | $24,000,000 | $17,000,000 |
| Machinery Furniture Equipment | $4,000,000 | $4,000,000 | $3,000,000 | $3,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $759,000,000 | $828,000,000 | $632,000,000 | $803,000,000 |
| Preferred Stock | - | - | - | $0 |
| Additional Paid In Capital | - | - | - | - |
| Long Term Capital Lease Obligation | - | - | - | - |
| Other Investments | - | - | - | - |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-484,000,000 | $-176,000,000 | $-330,000,000 | $432,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-482,000,000 | $-170,000,000 | $-306,000,000 | $438,000,000 |
| Cash Flow From Continuing Operating Activities | $-482,000,000 | $-170,000,000 | $-306,000,000 | $438,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-2,000,000 | $-6,000,000 | $-24,000,000 | $-6,000,000 |
| Investing Cash Flow | $66,000,000 | $-84,000,000 | $194,000,000 | $-413,000,000 |
| Cash Flow From Continuing Investing Activities | $66,000,000 | $-84,000,000 | $194,000,000 | $-413,000,000 |
| Net Other Investing Changes | - | - | - | $-3,000,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $429,000,000 | $228,000,000 | $25,000,000 | $0 |
| Financing Cash Flow | $488,000,000 | $277,000,000 | $33,000,000 | $33,000,000 |
| Cash Flow From Continuing Financing Activities | $488,000,000 | $277,000,000 | $33,000,000 | $33,000,000 |
| Net Common Stock Issuance | $429,000,000 | $228,000,000 | $25,000,000 | $0 |
| Common Stock Issuance | $429,000,000 | $228,000,000 | $25,000,000 | $0 |
| Net Other Financing Charges | - | $-7,000,000 | - | $10,000,000 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Issuance Of Debt | $49,000,000 | $47,000,000 | $0 | $0 |
| Interest Paid Supplemental Data | $7,000,000 | $1,000,000 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $5,000,000 | $3,000,000 |
| End Cash Position | $225,000,000 | $153,000,000 | $130,000,000 | $209,000,000 |
| Beginning Cash Position | $153,000,000 | $130,000,000 | $209,000,000 | $151,000,000 |
| Changes In Cash | $72,000,000 | $23,000,000 | $-79,000,000 | $58,000,000 |
| Proceeds From Stock Option Exercised | $10,000,000 | $9,000,000 | $8,000,000 | $23,000,000 |
| Net Issuance Payments Of Debt | $49,000,000 | $47,000,000 | $0 | $0 |
| Net Long Term Debt Issuance | $49,000,000 | $47,000,000 | $0 | $0 |
| Long Term Debt Issuance | $49,000,000 | $47,000,000 | $0 | $0 |
| Net Investment Purchase And Sale | $68,000,000 | $-78,000,000 | $218,000,000 | $-404,000,000 |
| Sale Of Investment | $1,144,000,000 | $965,000,000 | $1,006,000,000 | $837,000,000 |
| Purchase Of Investment | $-1,076,000,000 | $-1,043,000,000 | $-788,000,000 | $-1,241,000,000 |
| Net PPE Purchase And Sale | $-2,000,000 | $-6,000,000 | $-24,000,000 | $-6,000,000 |
| Purchase Of PPE | $-2,000,000 | $-6,000,000 | $-24,000,000 | $-6,000,000 |
| Change In Working Capital | $-194,000,000 | $22,000,000 | $-71,000,000 | $623,000,000 |
| Change In Other Working Capital | $-240,000,000 | $-56,000,000 | $-68,000,000 | $-112,000,000 |
| Change In Other Current Liabilities | $8,000,000 | $25,000,000 | $-3,000,000 | $21,000,000 |
| Change In Other Current Assets | $5,000,000 | $22,000,000 | $-14,000,000 | $2,000,000 |
| Change In Payables And Accrued Expense | $24,000,000 | $3,000,000 | $-1,000,000 | $8,000,000 |
| Change In Payable | $24,000,000 | $3,000,000 | $-1,000,000 | $8,000,000 |
| Change In Account Payable | $24,000,000 | $3,000,000 | $-1,000,000 | $8,000,000 |
| Change In Receivables | $9,000,000 | $28,000,000 | $15,000,000 | $704,000,000 |
| Other Non Cash Items | $8,000,000 | $10,000,000 | $10,000,000 | $11,000,000 |
| Stock Based Compensation | $60,000,000 | $76,000,000 | $73,000,000 | $65,000,000 |
| Asset Impairment Charge | $0 | $20,000,000 | $0 | $0 |
| Amortization Of Securities | $-13,000,000 | $-25,000,000 | $-19,000,000 | $0 |
| Depreciation Amortization Depletion | $10,000,000 | $10,000,000 | $8,000,000 | $6,000,000 |
| Depreciation And Amortization | $10,000,000 | $10,000,000 | $8,000,000 | $6,000,000 |
| Net Income From Continuing Operations | $-353,000,000 | $-283,000,000 | $-307,000,000 | $-267,000,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-3,000,000 |
| Sale Of Intangibles | - | - | $0 | $3,000,000 |
| Purchase Of Intangibles | - | - | $0 | $-6,000,000 |
| Common Stock Payments | - | - | - | - |
| Change In Accrued Expense | - | - | - | - |
| Change In Prepaid Assets | - | - | - | - |
| Changes In Account Receivables | - | - | - | - |
| Earnings Losses From Equity Investments | - | - | - | - |
Fetched: 2026-07-15